US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-associated

Funding Opportunity Number: RFA-IP-15-002 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.08393.185Eligible Applicants Others (see text field entitled "Additional Information on Eligibility" for clarification)Agency Name: HHS-CDCClosing Date: Mar 03, 2015Award Ceiling: $3,000,000Expected Number of Awards: 4Creation Date: Dec 31, 2014Funding Opportunity Description: Influenza is an important cause of morbidity, mortality, and healthcare burden across all age groups.
Because influenza viruses are constantly changing and vaccines are reformulated every year, annual
estimates of the effectiveness of influenza vaccines in preventing influenza infection and its
associated complications are needed in order to evaluate the protection provided by annual,
nationwide vaccination programs.Each year in the United States, influenza viruses infect up to 20%
of the population and cause thousands of hospitalizations and deaths; influenza-associated
hospitalization rates are highest among older adults, persons ≥ 65 years old. Annual influenza
vaccination is the primary influenza prevention strategy and is recommended for all people ≥ 6
months of age in the U.S. Many studies have described the vaccine effectiveness (VE) of seasonal
and 2009 pandemic influenza vaccine formulations against laboratory-confirmed symptomatic and
medically-attended outpatient infl...

Source: Grants.gov - January 1, 2015 Category: Research Tags: Health Source Type: funding